Niacin-laropiprant combination: novel approach not only to treatment of dyslipidemia

Abstract

Nicotinic acid (syn. niacine) is provitamine of nikotinamide, which is a part of coenzymes NAD+ (nicotinamide adenine dinucleotide) and NADP+ (nicotinamide adenine dinucleotide phosphate). Nicotinic acid was originally indicated for its vasodilating action.

Laropiprant as selective antagonist of prostaglandine receptors D2 (PGD2) can moderate vazodilatation causing by nicotinic acid.

Keywords

• niacin
• cardiovascular disease
• dyslipidemia
• HDL-c
• Lp (a)
• laropiprant